[Pharmacological studies on sufoxazine (Y-8894). (II). Anti-anoxic effect].
The anti-anoxic effect of sufoxazine was investigated in various cerebral anoxia models with mice, in comparison with those of various cerebroactive drugs. Sufoxazine reduced dose-dependently the duration of coma induced by a sublethal dose of KCN (1.8 mg/kg, i.v.), significantly stimulating recovery from the coma at 5 mg/kg, i.p. and 30 mg/kg, p.o. It also protected against a lethal dose of KCN (2.5 mg/kg, i.v.). Sufoxazine prolonged the survival time of mice subjected to hypobaric and normobaric hypoxia. Dihydroergotoxin and ifenprodil gave similar protection in the KCN-induced anoxia models, but produced adverse effects in the hypoxia models. Calcium hopantenate exerted similar but weak protection only at a dose as high as 300 mg/kg, i.p. These findings suggest that sufoxazine has an anti-anoxic action superior to those of the other cerebroactive drugs used.
D000818:Animals; D001274:Atmospheric Pressure; D003128:Coma / Q000139:chemically induced / Q000188:drug therapy; D004088:Dihydroergotoxine / Q000627:therapeutic use; D004359:Drug Therapy, Combination; D002534:Hypoxia, Brain / Q000139:chemically induced / Q000188:drug therapy*; D051379:Mice; D009025:Morpholines / Q000008:administration & dosage / Q000627:therapeutic use*; D010205:Pantothenic Acid / Q000031:analogs & derivatives / Q000627:therapeutic use; D010830:Physostigmine / Q000008:administration & dosage; D010880:Piperidines / Q000627:therapeutic use; D011190:Potassium Cyanide / Q000037:antagonists & inhibitors; D005680:gamma-Aminobutyric Acid / Q000031:analogs & derivatives / Q000627:therapeutic use
D009025:Morpholines; D010880:Piperidines; D004088:Dihydroergotoxine; C016030:pantogab; D010205:Pantothenic Acid; D005680:gamma-Aminobutyric Acid; C045330:sufoxazine; D010830:Physostigmine; D011190:Potassium Cyanide; C010739:ifenprodil